Changes to the Chemotherapies Used in the COG Stem Cell Transplant Regimen
The chemotherapeutic drugs used during stem-cell transplant for high-risk neuroblastoma appear to be changing in the current protocol used by the Children’s Oncology Group (COG). The current drug combination of carboplatin, etoposide, and melphalan (CEM) will transition to the combination that has been traditionally used in Europe — busulfan and melphalan (BuMel). The two regimens show similar rates of patient survival; however, the toxicities and side-effects associated with CEM were greater than those experienced with BuMel.
For more information, please see the press release.